The Second and Third Decade After 103Pd Plaque Brachytherapy for Choroidal Melanoma

Quick Take

This study evaluates the visual and ocular health of patients two to three decades after undergoing Palladium-103 (103Pd) plaque brachytherapy for choroidal melanoma. It aims to provide definitive data on the very long-term efficacy and safety profile of this specific radiation isotope in a large patient cohort.

Why It Matters

Long-term data exceeding 20 years is exceptionally rare in ocular oncology, yet it is crucial for understanding the full lifecycle of radiation-induced changes. As more patients survive their primary malignancy, clinicians need to know if 103Pd offers stable long-term ocular outcomes or if there is a significant decline in the second and third decades. This information is fundamental for patient counseling and the refinement of radiation protocols to balance tumor control with functional vision preservation.

Key Details

• Investigates outcomes specifically associated with Palladium-103 (103Pd) isotopes.
• Tracks patient outcomes into the second and third decades following initial brachytherapy.
• Focuses on both visual acuity and overall ocular health outcomes.
• Utilizes a large patient cohort to establish long-term prognostic trends.

Study Snapshot

Who's Affected